Woojeong Bio Establishes Biosafety Level 3 Facility for Infectious Disease Research Animals
[Asia Economy Reporter Lee Gwan-joo] Woojung Bio announced on the 13th that it has established the first animal-use biosafety level 3 (ABSL-3) facility among private companies in Korea.
The ABSL-3 facility, built on the 5th basement floor of the 'Woojung Bio New Drug Cluster,' is installed and operated in accordance with the 'Infectious Disease Prevention and Control Act' and the 'Act on the Transboundary Movement of Genetically Modified Organisms,' among others.
Woojung Bio plans to build additional infrastructure necessary for infectious disease treatment and vaccine development research, and expand preclinical research (CRO) services through collaboration with various institutions and companies.
Hot Picks Today
As Samsung Falters, Chinese DRAM Surges: CXMT Returns to Profit in Just One Year
- "Most Americans Didn't Want This"... Americans Lose 60 Trillion Won to Soaring Fuel Costs
- Man in His 30s Dies After Assaulting Father and Falling from Yongin Apartment
- Samsung Union Member Sparks Controversy With Telegram Post: "Let's Push KOSPI Down to 5,000"
- "Why Make Things Like This?" Foreign Media Highlights Bizarre Phenomenon Spreading in Korea
Cheon Byeong-nyeon, CEO of Woojung Bio, said, "Currently, there is a lack of preclinical trial infrastructure for infectious diseases in Korea, and most research facilities are operated to meet internal demands of public or educational institutions. We will provide facilities that bio ventures developing new drugs related to infectious diseases can utilize, thereby responding quickly to another infectious disease pandemic such as monkeypox and contributing to vaccine localization."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
